echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The State Food and Drug Administration approves the listing of Hengrui Medicine's Hytrapopapaethanolamine Tablets

    The State Food and Drug Administration approves the listing of Hengrui Medicine's Hytrapopapaethanolamine Tablets

    • Last Update: 2021-06-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    17, the State Food and Drug Administration announcement, recently listed by priority review approval procedures Class 1 drug innovation Haiqu Park Pa ethanolamine piece Jiangsu Hengrui Medicine Co.
    , Ltd.
    declared
    .

    This drug is an innovative drug independently researched and developed by China with independent intellectual property rights.
    It is used for chronic primary immune thrombocytopenia that has not responded well to treatments such as glucocorticoids and immunoglobulins due to thrombocytopenia and clinical conditions that increase the risk of bleeding.
    Adult patients with severe aplastic anemia (ITP), as well as adults with severe aplastic anemia (SAA) who do not respond well to immunosuppressive therapy
    .


    Among them, the SAA indication is conditional approval


    Herombopag Olamine is a small molecule human thrombopoietin receptor (TPO-R) agonist
    .


    According to relevant statistics, there are currently 5 approved TPO-R drugs in the world, including Lutrobopal, Eltrobopal, Romigrastim, Alvatrobopal, and Thrombopoietin; currently, approved domestically Among them are 3SBio's recombinant human thrombopoietin, Novartis's Eltropopa ethanolamine tablets, and Fosun Pharma's introduction of AkaRx, Inc.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.